Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. It manufactures and commercializes Hexvix/Cysview, its flagship product, for more precise detection and resection of non-muscle invasive bladder cancer (NMIBC), reduction of disease recurrence and progression rates, and improved and cost-effective patient outcomes. Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLC). The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment is involved in the development of pipeline products. The company was founded on August 27, 1993 and is headquartered in Oslo, Norway.
EURONEXT OSLO